Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Gains from Investment Securities (2018 - 2025)

10x Genomics' Gains from Investment Securities history spans 7 years, with the latest figure at $11.4 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities changed N/A year-over-year to $11.4 million; the TTM value through Dec 2025 reached $11.4 million, changed N/A, while the annual FY2025 figure was $11.4 million, N/A changed from the prior year.
  • Gains from Investment Securities for Q4 2025 was $11.4 million at 10x Genomics, up from -$462000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $16.6 million in Q4 2022 and bottomed at -$16.6 million in Q3 2022.
  • The 5-year median for Gains from Investment Securities is $231500.0 (2024), against an average of $1.8 million.
  • The largest annual shift saw Gains from Investment Securities crashed 4707.81% in 2021 before it skyrocketed 9766.67% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$8.3 million in 2021, then surged by 299.11% to $16.6 million in 2022, then crashed by 113.54% to -$2.2 million in 2023, then surged by 100.04% to $1000.0 in 2024, then soared by 1139600.0% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Gains from Investment Securities are $11.4 million (Q4 2025), -$462000.0 (Q2 2025), and $462000.0 (Q1 2025).